Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Crinetics Pharmaceuticals Inc shares valued at $209,050 were sold by Pizzuti Dana on Oct 01 ’25. At $41.81 per share, Pizzuti Dana sold 5,000 shares. The insider’s holdings dropped to 66,270 shares worth approximately $2.93 million following the completion of this transaction.
Also, DANA PIZZUTI purchased 5,000 shares, netting a total of over 208,250 in proceeds.
Before that, Struthers Richard Scott had sold 4,000 shares from its account. In a trade valued at $180,000, the President & CEO traded Crinetics Pharmaceuticals Inc shares for $45.00 each. Upon closing the transaction, the insider’s holdings decreased to 4,000 shares, worth approximately $4.68 million.
As published in their initiating research note from Goldman on July 10, 2025, Crinetics Pharmaceuticals Inc [CRNX] has been a Neutral and the price target has been revised to $36. Analysts at Stifel started covering the stock with ‘”a Buy”‘ outlook in a report released in late March. As of February 11, 2025, TD Cowen has initiated its “Buy” rating for CRNX. Earlier on February 04, 2025, Wolfe Research initiated its rating. Their recommendation was “a Peer perform” for CRNX stock.
Analyzing CRNX Stock Performance
On last trading session, Crinetics Pharmaceuticals Inc [NASDAQ: CRNX] rose 0.23% to $44.15. The stock’s lowest price that day was $44.0957, but it reached a high of $45.95 in the same session. During the last five days, there has been a drop of approximately -0.63%. Over the course of the year, Crinetics Pharmaceuticals Inc shares have dropped approximately -16.92%.
Is Crinetics Pharmaceuticals Inc subject to short interest?
Stocks of Crinetics Pharmaceuticals Inc saw a sharp steep in short interest on 2025-09-30 dropping by -1.6 million shares to 12.38 million. Data from Yahoo Finance shows that the short interest on 2025-08-29 was 13.98 million shares. A decline of -12.92% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.33 of the overall float, the days-to-cover ratio (short ratio) decline to 6.33.
Which companies own the most shares of Crinetics Pharmaceuticals Inc (CRNX)?
In terms of Crinetics Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 82 in the next 12 months, up nearly 86.15% from the previous closing price of $44.05. Analysts anticipate Crinetics Pharmaceuticals Inc stock to reach 143 by 2025, with the lowest price target being 36. In spite of this, 5 analysts ranked Crinetics Pharmaceuticals Inc stock as Buy at the end of 2025. On January 22, 2025, Jefferies assigned a price target of “a Buy” to the stock and upgraded coverage with a $55.
